Notably, tumors with elevated FOXM1 share many features with MPNSTs that are resistant to CDK4/6-MEK inhibition, most of which reflect extra-tumoral changes that suppress anti-cancer immunity [38, 39] (Figure 2). This evidence concerns the gene MAP2K7 and cancer.